Monitoring
GAD is a chronic, fluctuating, remitting and relapsing disorder that generally requires long-term treatment.[52] After an acute trial of pharmacotherapy over 12 weeks, effective treatment should be continued for at least 12 months. Patients should be monitored throughout this period to ensure continued benefit. A trial taper from the medication may be made at that time, with treatment reinstated if relapse occurs.[40] Several medications shown to be effective for short-term treatment have also been shown to be effective for relapse prevention.[221][222]
Use of this content is subject to our disclaimer